National and Kapodistrian University of Athens
Μοριακοί μηχανισμοί ανταπόκρισης στη χημειοθεραπεία με πλατίνη: μελέτη σε ασθενείς με καρκίνο ωοθηκών
Abstract
dc:descriptionIntroduction: Ovarian cancer is the fourth cause of death among all gynecologic cancers. Although platinum drugs have produced higher overall response rates and an increase in median survival, a relevant clinical problem in the treatment of advanced ovarian cancer is the development of tumor resistance to platinum compounds. The mechanism of platinum resistance is multifactorial, but DNA repair plays the most important role.Purpose: One of the objectives of this thesis was to investigate the repair of DNA damage induced by platinum drugs. Although our previous data showed that the levels of DNA damage may serve as a biomarker predictive of patient therapeutic response, the assays used for the measurement of gene specific DNA repair are fairly time-consuming, and require complex procedures such as Southern transfer and hybridization. Therefore, we developed three different methods, multiplex Q-PCR, alkaline comet assay and induction of gammaH2Ax, which are rapid and convenient methodologies of wider applicability and suitable for application in a clinical context. The second goal was the investigation of the molecular pathways which are induced after the formation of these adducts. The ultimate aim of this study was to develop and validate an appropriate molecular biomarker for prediction of patient response to chemotherapy with platinum drugs. Materials and Methods: Platinum-induced DNA damage formation/repair was measured in HepG2 cells and peripheral blood mononuclear cells (PBMC) from 9 healthy volunteers and 18 patients with ovarian cancer, using Southern blot analysis and quantitative PCR assay. Then, using immunocytochemistry, we investigated the induction of key components of the DNA damage response pathway, such as gammaH2Ax, ATR, ATM, Chk1 and Chk2, after treatment of HepG2 cells with platinum drugs. Results: Using HepG2 cells, we found the appropriate conditions to measure DNA damage. The adduct levels measured by Q-PCR were very similar to the levels of total DNA adducts measured by Southern blot analysis, suggesting that Q-PCR measures cisplatin-induced total adducts. Another observation is that cisplatin-induced intrastrand cross-link levels reached a plateau within ~3h of treatment, while peak interstrand cross-links were observed at ~24h.Carboplatin induced maximal levels of both intra- and interstrand cross-links were observed within 24h of drug incubation. In the second part of our report, we investigated ATM-ATR pathways after exposure to platinum drugs. Using immunocytochemistry, gammaH2Ax was rapidly activated, followed by the sequential induction of the ATR and ATM pathways, after treatment of HepG2 cells with platinum drugs. Finally, using multiplex Q-PCR, alkaline comet assay and gammaH2Ax staining, we measured the DNA damage in the ex vivo platinum-treated lymphocytes of 9 healthy volunteers and 18 patients with ovarian cancer. Application of the alkaline comet assay showed that significantly greater DNA damage was found in the group of patients sensitive to subsequent chemotherapy compared to resistant ones [13927,42 Olive Tail Moment for sensitive and 7834,25 for resistant, p=0.05]. Also, using immunocytochemistry, we examined the induction of gammaH2Ax and found very similar results to those obtained using alkaline comet assay (p=0,058). Moreover, patients with ovarian cancer showed greater endogenous DNA damage than healthy volunteers (p=0,01). Finally, using immunocytochemistry, we found that healthy volunteers had more panuclear stained cells than patients, indicating that because the latters had suppressed the apoptotic pathway (p=0,01). Conclusion: In the present study, we focused on the molecular mechanisms of DNA damage response pathways (gammaH2Ax, ATR, ATM, Chk1 and Chk2) and the possible implications in the malignant transformation of the disease and the outcome of platinum-based chemotherapy. We found that changes in the DNA repair efficiency as measured in PBMCs from ovarian cancer patients are implicated in both the malignant transformation of the disease and the clinical response to platinum chemotherapy. These data might eventually be translated into novel indicators for the early detection of the disease and the selection of patients who are more likely to benefit from platinum chemotherapy.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Stefanou, Dimitra
- Στεφάνου, Δήμητρα
Subjects
dc:subject × 14Rights
dc:rights- Statement dc:rights
-
- BY_NC_SA
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/41726